series-b
Stage
2006
Founded
1
Investors
About
OSE Immunotherapeutics is a clinical-stage biotech company developing first-in-class therapies in immuno-oncology and immuno-inflammation. The company is leading a 36-month program named “HexARN” to develop novel RNA therapeutics and delivery methods for inflammatory disorders and autoimmune diseases.
Explore OSE Immunotherapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.